Structure via PubChem · Public domain (PubChem)
prulifloxacin
Sign in to savePrulifloxacin is an older synthetic antibiotic of the fluoroquinolone class undergoing clinical trials prior to a possible NDA (New Drug Application) submission to the U.S. Food and Drug Administration (FDA). It is a prodrug which is metabolized in the body to the active compound ulifloxacin. It was developed over two decades ago by Nippon Shinyaku Co. and was patented in Japan in 1987 and in the United States in 1989.
Chemical data
- Formula
- C21H20FN3O6S
- Molecular weight
- 461.5 g/mol
- IUPAC name
- 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
- SMILES
- CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C
- InChIKey
- PWNMXPDKBYZCOO-UHFFFAOYSA-N
- XLogP
- 1
- Polar surface area
- 125 Ų
- H-bond donors
- 1
- H-bond acceptors
- 11
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- chronic bronchitis, urinary tract infection, gastroenteritis, prostatitis
via ChEMBL · EBI
Research
166 papers- Prulifloxacin.Drugs · 2004
- Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections.International journal of antimicrobial agents · 2011
- Prulifloxacin: a new antibacterial fluoroquinolone.Expert review of anti-infective therapy · 2006
- Prulifloxacin: clinical studies of a broad-spectrum quinolone agent.Future microbiology · 2009
- Pharmacologic characteristics of prulifloxacin.Pulmonary pharmacology & therapeutics · 2006
via PubMed
Wikidata facts
- Subclass of
- carboxylic acid
- Mass
- 461.106
- Has use
- medication
Show 3 more facts
- chemical formula
- C₂₁H₂₀FN₃O₆S
- canonical SMILES
- CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C
- Commons category
- Prulifloxacin
Sources (2)
via Wikidata · CC0
~8 min read
Encyclopedic overview
16 sectionsContents
- History
- Licensed uses
- Availability
- Mechanism of action
- Contraindications
- Special populations
- Pregnancy
- Pediatric population
- Special precautions
- Adverse Events
- Interactions
- Overdose
- Pharmacokinetics
- See also
- References
- Bibliography
Prulifloxacin is an older synthetic antibiotic of the fluoroquinolone class undergoing clinical trials prior to a possible NDA (New Drug Application) submission to the U.S. Food and Drug Administration (FDA). It is a prodrug which is metabolized in the body to the active compound ulifloxacin. It was developed over two decades ago by Nippon Shinyaku Co. and was patented in Japan in 1987 and in the United States in 1989.
It has been approved for the treatment of uncomplicated and complicated urinary tract infections, community-acquired respiratory tract infections in Italy and gastroenteritis, including infectious diarrheas, in Japan. Prulifloxacin has not been approved for use in the United States.
Excerpted from Wikipedia’s “prulifloxacin” article, available under the CC BY-SA 4.0 licence.